Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.
The single- and multiple-dose pharmacokinetics of and tolerability to a new microfluidized suspension of atovaquone were studied in human immunodeficiency virus-seropositive patients with CD4 counts of < or = 200 cells per mm3 in order to define a dosing regimen for the treatment of Pneumocystis car...
Сохранить в:
| Опубликовано в:: | Antimicrob Agents Chemother |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Microbiology (ASM)
1996
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163157/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8851570/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.40.3.556 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|